NEW YORK – Oxford BioTherapeutics and Boehringer Ingelheim said on Thursday they are extending an ongoing collaboration focused on developing cancer immunotherapies for another two years.
The collaboration is using Oxford's drug discovery platform, OGAP, to identify cell-surface cancer targets for Boehringer Ingelheim's immuno-oncology and antibody drug conjugate platforms.
Under the agreement, Boehringer Ingelheim is responsible for the development and commercialization of candidates for the novel targets identified by OGAP. Oxford will receive research funding to identify the targets along with success-based development and regulatory milestone payments and royalties on potential future product sales.
The two firms have had two collaborations focused on drug discovery that have spanned 10 years, according to Oxford CEO Christian Rohlff.
"Over the past decade, we have built a successful relationship with Boehringer Ingelheim's cancer research, now in its third phase, through high-quality outputs enabled by our proprietary OGAP discovery platform," Rohlff said in a statement. "Since 2013, the company has selected three targets discovered using OGAP, of which two programs have led to therapeutic assets in Phase I clinical development."
Oxford has similar drug discovery partnerships with Genmab, ImmunoGen, Agenus, GORTEC (Groupe d'Oncologie Radiothérapie Tête Et Cou), and Kite.